2-溴-4-碘-5-氯吡啶 | 1061357-88-7

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-4-碘-5-氯吡啶
• 英文名称: 2-bromo-5-chloro-4-iodopyridine
• CAS: 1061357-88-7
• 化学式: C₅H₂BrClIN
• 分子量: 318.339
• InChiKey: UPWHKYFBMYMQJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  2-溴-4-碘-5-氯吡啶 在 四(三苯基膦)钯 、 palladium diacetate 、 potassium carbonate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 5-chloro-4-(1-methyl-1H-pyrazol-3-yl)-N-(4-morpholinophenyl)pyridin-2-amine
  参考文献：
  名称：

  Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors

  摘要：

  The design and synthesis of a novel series of c-jun N-terminal kinase (JNK) inhibitors is described. The development of the 4-(pyrazol-3-yl)-pyridine series was discovered from an earlier pyrimidine series of JNK inhibitors. Through the optimization of the scaffold 2, several potent compounds with good in vivo profiles were discovered. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.104
• 作为产物：
  描述：

  2-溴-5-氯吡啶 在 正丁基锂 、 二异丙胺 、 碘 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 2-溴-4-碘-5-氯吡啶
  参考文献：
  名称：

  [EN] HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE
  [FR] MODULATEURS HÉTÉROCYCLIQUES DE GPR119 POUR LE TRAITEMENT D'UNE MALADIE

  摘要：

  公开号：

  WO2009117421A3

文献信息

• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS DE LA KINASE CYCLINE-DÉPENDANTE 7 (CDK7)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2016058544A1

  公开（公告）日：2016-04-21

  The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式（I）的新化合物及其药学上可接受的盐、溶剂化合物、水合物、互变异构体、立体异构体、同位素标记衍生物及其组合物。还提供了涉及这些化合物或组合物用于治疗或预防增生性疾病（例如，癌症（例如，白血病、黑色素瘤、多发性骨髓瘤）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增生性疾病的受试者可能抑制细胞周期依赖性激酶（例如，CDK7）的异常活性，从而诱导受试者的细胞凋亡和/或抑制转录。
• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS DE CYCLINE-DÉPENDANTE KINASE 7 (CDK7)
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2014063068A1

  公开（公告）日：2014-04-24

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式（I）的新化合物，以及药学上可接受的盐、溶剂化合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和其组合物。还提供了涉及这些创新化合物或组合物的方法和工具包，用于治疗或预防增殖性疾病（例如癌症（例如白血病、淋巴瘤、黑色素瘤、多发性骨髓瘤、乳腺癌、尤因肉瘤、骨肉瘤、脑癌、神经母细胞瘤、肺癌）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫疾病）的方法。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者可能抑制激酶的异常活性，例如细胞周期依赖性激酶（CDK）（例如细胞周期依赖性激酶7（CDK7）），从而诱导受试者的细胞凋亡和/或抑制转录。
• INHIBITORS OF FOCAL ADHESION KINASE
  申请人：Liang Congxin

  公开号：US20110046121A1

  公开（公告）日：2011-02-24

  The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.

  该发明提供了聚焦粘附激酶的抑制剂，该酶参与细胞的细胞骨架与细胞外基质的附着，已被证实与细胞迁移、细胞增殖和细胞存活等过程有关。这些抑制剂是5-取代的2,4-二氨基吡啶的衍生物，其中取代基如本文所定义。该发明还提供了使用这些抑制剂治疗癌症的方法，以及通过使用偶联反应制备这些抑制剂的方法。
• INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20160122323A1

  公开（公告）日：2016-05-05

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式（I）的新型化合物及其药学上可接受的盐、溶剂合物、水合物、多晶形、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和其组合物。本发明还提供了使用所述创新化合物或组合物治疗或预防增殖性疾病（例如，癌症（例如，白血病、淋巴瘤、黑色素瘤、多发性骨髓瘤、乳腺癌、尤因氏肉瘤、骨肉瘤、脑癌、神经母细胞瘤、肺癌）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可以抑制激酶的异常活性，例如细胞周期依赖性激酶（CDK）（例如细胞周期依赖性激酶7（CDK7）），从而在受试者中诱导细胞凋亡和/或抑制转录。
• ERK INHIBITOR AND USE THEREOF
  申请人：Betta Pharmaceuticals Co., Ltd

  公开号：EP3805217A1

  公开（公告）日：2021-04-14

  Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.

  公开了一种作为细胞外信号调节激酶（ERK）抑制剂的化合物（如式 I 所示）、其药物组合物、其制备方法以及其在治疗 ERK 介导的疾病中的用途。所述化合物通过调节细胞增殖、凋亡、迁移和血管生成等多个过程发挥作用。